Table 2. Correlations of tumor response and clinical characteristics.
| Characteristic | Number | PR | SD | PD | P -Value |
|---|---|---|---|---|---|
| Total | 25 | 8 | 12 | 5 | |
| Age(years) | 0.084 | ||||
| <60 | 13 | 2 | 9 | 2 | |
| ≧60 | 12 | 6 | 3 | 3 | |
| Gender | 0.198 | ||||
| Male | 16 | 4 | 7 | 5 | |
| Female | 9 | 4 | 5 | 0 | |
| ECOG PS | 0.62 | ||||
| 0 | 12 | 3 | 7 | 2 | |
| 1 | 13 | 5 | 5 | 3 | |
| Stages | 0.883 | ||||
| IVA | 10 | 4 | 3 | 3 | |
| IVB | 10 | 3 | 6 | 1 | |
| IVC | 5 | 1 | 3 | 1 | |
| Tumor localization | 0.52 | ||||
| Ascending colon | 6 | 1 | 4 | 1 | |
| Transverse colon | 1 | 1 | 0 | 0 | |
| Descending colon | 3 | 1 | 0 | 2 | |
| Sigmoid colon | 8 | 3 | 4 | 1 | |
| Rectum | 7 | 2 | 4 | 1 | |
| Differentiation grade | 0.615 | ||||
| 1 | 1 | 0 | 1 | 0 | |
| 2 | 17 | 7 | 7 | 3 | |
| 3 | 7 | 1 | 4 | 2 | |
| Line of therapy | 0.223 | ||||
| First | 9 | 5 | 2 | 2 | |
| Second | 10 | 2 | 7 | 1 | |
| Third | 6 | 1 | 3 | 2 | |
| Associated therapy | 0.852 | ||||
| FOLFOX6 | 4 | 2 | 2 | 0 | |
| FOLFIRI | 7 | 1 | 4 | 2 | |
| CT+B | 10 | 3 | 5 | 2 | |
| CT+Cetuximab | 4 | 2 | 1 | 1 | |
| Smoking history | 0.791 | ||||
| No | 21 | 6 | 10 | 5 | |
| Yes | 4 | 2 | 2 | 0 | |
| Alcohol-drinking history | 1 | ||||
| No | 22 | 7 | 10 | 5 | |
| Yes | 3 | 1 | 2 | 0 | |
| First-degree relative cancer history | 0.68 | ||||
| No | 23 | 8 | 10 | 5 | |
| Yes | 2 | 0 | 2 | 0 |
P value ≤0.05 was considered statistically significant.
ECOG, Eastern Cooperative Oncology Group; PS, performance status; CT, chemotherapy B, bevacizumab; PR: Partial response; SD: Stable disease; PD: Progression disease.